Clene Inc. (CLNN) Stock

About Clene Inc.

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

Clene Inc. is led by CEO Robert Etherington, employs 75 people, headquartered in US, publicly traded since 2018.

Clene Inc. (CLNN) stock trades at $5.29 with a market capitalization of $54.53M. The stock is valued at a price-to-earnings (P/E) ratio of -1.66, price-to-book of -3.34, price-to-sales of 414.62. Over the past 52 weeks the stock has ranged between $3.25 and $13.50, and currently trades 60.8% below its 52-week high.

On profitability, Clene Inc. generates a return on equity (ROE) of 233.93% — well above the market average, a sign of a high-quality business, return on capital employed of -139.38%, an operating margin of 0.00%, a net profit margin of -250.10%.

Official website: clene.com